Our Approach
Developing
breakthrough
products.
We have an emerging pipeline of programs to prevent disease progression, improve outcomes and protect against organ damage in cardio, renal and metabolic diseases.
RBT-1 (stannic protoporfin / iron sucrose)
Renibus’ second late-stage program RBT-1, recently completed the PROTECT Phase 3 trial in patients undergoing cardiac surgery. The results suggest that further development in higher-risk patients may be warranted, which is currently being evaluated.
Veverimer
Veverimer is a non-absorbed polymer that binds hydrochloric acid (HCl) in the stomach and is designed to increase serum bicarbonate concentrations without the addition of sodium or potassium. Veverimer is in Phase 3 development for the treatment of adults with chronic kidney disease and metabolic acidosis.
Publications
- VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis
Navdeep Tangri, Vandana S. Mathur , David A. Bushinsky, Gerrit Klaerner, Elizabeth Li, Dawn Parsell, Yuri Stasiv, Michael Walker, Donald E. Wesson, David C. Wheeler, Vlado Perkovic, and Lesley A. Inker - Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
David A. Bushinsky, Thomas Hostetter, Gerrit Klaerner, Yuri Stasiv, Claire Lockey, Sarah McNulty, Angela Lee, Dawn Parsell, Vandana Mathur, Elizabeth Li, Jerry Buysse, and Robert Alpern - Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trialDonald E Wesson, Vandana Mathur, Navdeep Tangri, Yuri Stasiv, Dawn Parsell, Elizabeth Li, Gerrit Klaerner, David A Bushinsky
- Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extensionDonald E Wesson, Vandana Mathur, Navdeep Tangri, Yuri Stasiv, Dawn Parsell, Elizabeth Li, Gerrit Klaerner, David A Bushinsky
- Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney DiseaseGerrit Klaerner, Jun Shao, Kalpesh Biyani, Matthew Kade, Paul Kierstead, Randi Gbur, Scott Tabakman, Son Nguyen, and Jerry Buysse
- Parenterial iron sucrose-induced renal preconditioning: differential ferritin heavy and light chain expression in plasma, urine, and internal organsAli C. Johnson, Ted Gooley, Alvaro Guillem, Jeff Keyser, Henrik Rasmussen, Bhupinder Singh, and Richard A. Zager
- Oxidant- induced preconditioning: A pharmacologic approach for triggering renal ‘self defense’Richard A Zager
- Quercetin and tin protoporphyrin attenuate hepatic ischemia reperfusion injury: role of HO-1Yara Atef & Hassan M. El-Fayoumi & Yousra Abdel-Mottaleb & Mona F. Mahmoud
- Inhibition of Heme Oxygenase-1 Protects Against Tissue Injury in Carbon Tetrachloride Exposed LiversChristian Eipel, Ph.D., Michaela Eisold, Harald Schuett, and Brigitte Vollmar, M.D.
- Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac hypertrophy in 5/6 nephrectomized ratsWei Ling Lau, Mahyar Khazaeli, Javad Savoj, Kasim Manekia, Maria Bangash, Roshni G. Thakurta, Anhthu Dang, Nosratola D. Vaziri, Bhupinder Singh
- Influence of Tetrahydrocurcumin on Hepatic and Renal Functional
Markers and Protein Levels in Experimental Type 2 Diabetic RatsPidaran Murugan and Leelavinothan Pari - Tetrahydrocurcumin Ameliorates Kidney Injury and High Systolic Blood Pressure in High-Fat Diet-Induced Type 2 Diabetic MiceWeerapon Sangartit, Kyung Bong Ha, Eun Soo Lee, Hong Min Kim, Upa Kukongviriyapan, Eun Young Lee, Choon Hee Chung
- Tetrahydrocurcumin protects against sepsis-induced acute kidney injury via the SIRT1 pathwayLu Lia, Xiaoxi Liua, Shasha Lia, Qingyan Wang, Hongru Wang, Menglu Xua and Yanxin An